THE SILCSBIO DIFFERENCE
SILCS
Site-Identification by Ligand Competitive Saturation
Our proprietary CADD software technology, SILCS, generates highly accurate 3D free energy maps called “FragMaps” which account for conformational nuances to reveal hidden pockets of opportunity.
SILCS FragMaps technology gives you an intuitive way of interacting with and visualizing the entire protein surface, further enabling your drug discovery team to:
- Accelerate drug discovery timelines
- Enhance high throughput screening to drive hit selection
- Reduce drug development costs
- Bolster drug development pipelines
SILCS
Site-Identification by Ligand Competitive Saturation
Our proprietary CADD software technology, SILCS, generates highly accurate 3D free energy maps called “FragMaps” which account for conformational nuances to reveal hidden pockets of opportunity.
SILCS FragMaps technology gives you an intuitive way of interacting with and visualizing the entire protein surface, further enabling your drug discovery team to:
- Accelerate drug discovery timelines
- Enhance high throughput screening to drive hit selection
- Reduce drug development costs
- Bolster drug development pipelines
WHY SILCSBIO OUTPERFORMS ALL OTHERS
SILCS is built on rigorous free energy calculations employing:
- Multiple small molecule probes with diverse functional groups
- Explicit solvent modeling
- Target molecule flexibility
- Advanced sampling methods (GCMC/MD) to identify cryptic pockets
WHY SILCSBIO OUTPERFORMS ALL OTHERS
SILCS is built on rigorous free energy calculations employing:
- Multiple small molecule probes with diverse functional groups
- Explicit solvent modeling
- Target molecule flexibility
- Advanced sampling methods (GCMC/MD) to identify cryptic pockets
OUR TEAM
Our team is committed to delivering the fastest, most reliable drug designs for your highest value drug programs. We are committed to providing our expertise and technology to unlock a whole new world of possibilities for you and your team.
OUR PARTNERS AND COLLABORATORS
SilcsBio Co-Founder Alex MacKerell, PhD Receives ACS Award for Computers in Chemical and Pharmaceutical Research
Dr. MacKerell to be honored at the ACS Spring 2022 National Meeting, March 20-24, in San Diego March 10, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, announced today its Co-Founder and Chief Scientific Officer, Alexander D. MacKerell Jr., [...]
